Calcium hydroxylapatite fillers
Injectable fillers using calcium hydroxylapatite microspheres in a gel carrier. Discussed for contour support; biostimulatory framing varies by product and indication.
Procedure Intelligence is for learning only. It does not decide whether a procedure is right for you—a qualified clinician should review your goals, history, skin, and medications. Important Information
What it is
Injectable fillers using calcium hydroxylapatite microspheres in a gel carrier. Discussed for contour support; biostimulatory framing varies by product and indication.
Treatment type: Injectable filler. Performed by a qualified clinician.
Also searched as: CaHA, Radiesse-type filler education
Typical U.S. cost
About $600–$1,800 per syringe
Estimated U.S. range. Actual cost varies by provider, location, treatment area, product/device, and treatment intensity.
This figure is priced per syringe—not per treatment.
How it generally works
CaHA particles in a carrier gel provide immediate structural support; surrounding tissue responses are discussed in the clinical literature as part of longer-horizon contour education.
Quorenne does not include operational instructions, device settings, injection maps, dosing, or procedural technique.
What people commonly explore it for
These are topics commonly discussed for this technology—not a match to your skin or a statement that this option is right for you:
- Volume loss
- Laxity
Areas commonly treated in educational literature include: Face, Hands, Varies by indication.
Common products
Educational brand and product-family literacy for biostimulators. Quorenne does not recommend one product over another, provide dosing, or select providers.
What it may not address well
- Fine etched lines that need different modalities
- Pigment or vascular concerns
- Expectations of reversible HA-like dissolution in all cases
Additional limitations:
- Not interchangeable with HA fillers for every indication
- Dissolution options differ from HA gels
- Not a substitute for surgical lifting when laxity is significant
What the experience may involve
- Goals and anatomy review
- Product and indication discussion including approved vs off-label use
- Injection visit
- Follow-up for contour settling
Comfort context: Clinicians may discuss local comfort measures; Quorenne does not teach injection technique.
Session pattern: Consultation and treatment visit; additional sessions only if a clinician recommends them.
Recovery spectrum: Short recovery
Short recovery: temporary effects often settle over a brief period, but individual experiences vary and results are not promised.
Results and durability
Onset: Immediate contour support may be visible, with settling as swelling resolves.
Durability: Often discussed longer than many HA gels, but still not permanent; individual duration varies.
Results vary. Some effects are temporary. Multiple sessions may sometimes be discussed. Maintenance may be relevant. Individual response cannot be predicted by Quorenne.
Risks and considerations
Common temporary effects
- Swelling
- Bruising
- Firmness or nodules that may soften
Less common but important risks
- Persistent nodules
- Vascular events
- Infection
Rare but serious risks
- Tissue injury from vascular compromise
- Vision-threatening events
Discuss pregnancy, lactation, medications, and medical history with your clinician before any procedure. Quorenne does not declare individual safety.
Skin-tone and pigment considerations
Bruising visibility and post-inflammatory pigment deserve discussion across skin tones.
Inflammation-related pigment change can occur in susceptible individuals after bruising.
Scarring is uncommon; complications still require prompt clinical care.
High-risk facial zones require experienced injectors; eye symptoms need emergency evaluation.
More clinical details
Regulatory context
Status label: Varies by product and indication
Specific CaHA products have FDA approvals for labeled indications. Expanding use to unlabeled areas may be off-label and should be disclosed in consent.
Regulatory language is indication-, product-, and region-specific. An entire category is not automatically approved for every use.
Questions to ask your clinician
- What are your training and experience with this procedure?
- What product or device would be used?
- Is that use approved or cleared for this indication?
- What alternatives should I consider?
- What risks are most relevant to my medical history and skin tone?
- What results are realistic for someone like me?
- What is the expected recovery?
- How are complications recognized and managed?
- Who will perform the procedure?
- What follow-up is available?
Skincare discussions around procedures
Clinicians often discuss supportive skincare themes. Quorenne does not tell you exactly when to stop or restart medications, prescriptions, retinoids, acids, anticoagulants, supplements, or actives—those decisions belong with the treating clinician.
- Sun protection before and after procedures is commonly discussed
- Barrier support and gentle cleansing are often part of clinician aftercare conversations
- Temporary pauses of certain active ingredients may be discussed—timing is individualized
- Moisturizer use and irritation avoidance are frequently reviewed
- Prescription, medication, and supplement decisions belong with the treating clinician
Related educational support themes:
- Sunscreen
- Gentle moisturizer
When to seek medical evaluation
- Seek prompt medical care for rapidly changing, painful, bleeding, infected, or otherwise worrisome skin findings.
- Urgent symptoms after any procedure—such as severe pain, vision changes, spreading redness, fever, or breathing difficulty—require emergency care, not Quorenne.
- Quorenne does not triage or diagnose skin conditions.
Evidence and sources
Evidence confidence: Moderate evidence base
Labeled indication data and clinical experience support educational use of the category; comparative durability claims should stay product-specific.
Known uncertainties:
- Biostimulatory contribution varies by protocol and individual biology
- Long-horizon nodule management approaches continue to evolve
Sources
- FDA labeling for approved calcium hydroxylapatite filler products (labeling)
Last reviewed: 2026-08-05
Editorial status: published